Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  1997-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0360-3016(97)00303-9PMID 9276374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quiescence in R3327-G rat prostate tumors after androgen ablation.

  1997cited by this paper
• The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study.

  1997cited by this paper
• Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

  1997cited by this paper
• Relationship among hormonal treatments, suppression of spermatogenesis, and testicular protection from chemotherapy-induced damage.

  1996cited by this paper
• 127Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the eortc radiotherapy and genito-urinary tract cancer cooperative groups

  1996cited by this paper
• Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

  1995cited by this paper
• Implication of cell kinetic changes during the progression of human prostatic cancer.

  1995cited by this paper
• Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

  1995cited by this paper
• 97 A randomized trial comparing local tumor control following irradiation alone versus combined androgen withdrawal and irradiation in an androgen sensitive prostate cancer xenograft

  1995cited by this paper
• Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.

  1995cited by this paper
• Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.

  1995cited by this paper
• Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.

  1995cited by this paper
• Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer

  1995cited by this paper
• Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel.

  1994cited by this paper
• Reemergence of apoptotic cells between fractionated doses in irradiated murine tumors.

  1994cited by this paper
• Castration‐induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice

  1993cited by this paper
• Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies.

  1993cited by this paper
• Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate, but not in the highly differentiated dunning R3327 prostatic adenocarcinoma

  1993cited by this paper
• Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays.

  1993cited by this paper
• Protection by gonadal steroid hormones against procarbazine-induced damage to spermatogenic function in LBNF1 hybrid rats.

  1993cited by this paper
• Development of apoptosis in irradiated murine tumors as a function of time and dose.

  1993cited by this paper
• Application of the Monoclonal Antibody Ki-67 on Prostate Biopsies to Assess the Proliferative Cell Fraction of Human Prostatic Carcinoma

  1991cited by this paper
• Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma.

  1991cited by this paper
• Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration

  1989cited by this paper
• Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

  1988cited by this paper
• Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring.

  1987cited by this paper
• Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: dependency on tumor type.

  1986cited by this paper
• In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.

  1983cited by this paper
• Hormone sensitivity of the R3327-G rat prostate adenocarcinoma: growth rate, DNA content, and hormone receptors.

  1982cited by this paper
• Factors influencing the repair of potentially lethal radiation damage in growth-inhibited human cells.

  1973cited by this paper

• Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis of randomized controlled trials

  2023cites this paper
• Mechanisms, Challenges, and Opportunities in Combined Radiation and Hormonal Therapies.

  2022cites this paper
• Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases.

  2020cites this paper
• Salvage radiation therapy for prostate cancer patients after prostatectomy

  2019cites this paper
• Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer

  2019cites this paper
• Adjuvant androgen-deprivation therapy following prostate total cryoablation in high-risk localized prostate cancer patients - Open-labeled randomized clinical trial.

  2018cites this paper
• Évaluation du traitement par radiothérapie externe chez des patients porteurs d’un cancer de la prostate entre 2000 et 2015 au CHU de Grenoble

  2018cites this paper
• Basic Concepts of Clinical Radiation Oncology

  2017cites this paper
• Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone

  2017cites this paper
• Radioterapia externa en el tratamiento del cáncer de la próstata: experiencia personal 1993-2015

  2016cites this paper
• Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

  2016cites this paper
• A genetic basis for the variation in the vulnerability of cancer to DNA damage

  2016cites this paper
• Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy

  2016cites this paper
• The androgen receptor for the radiation oncologist.

  2015cites this paper
• Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.

  2015cites this paper
• Recent Developments in Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

  2014cites this paper
• Hormonal Therapy and Radiation Therapy: Randomized and Prospective Trials

  2014cites this paper
• A Comprehensive Review of Contemporary Role of Local Treatment of the Primary Tumor and/or the Metastases in Metastatic Prostate Cancer

  2014cites this paper
• Murine Models of Prostate Cancer

  2013cites this paper
• High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy

  2013cites this paper
• Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer

  2013cites this paper
• Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial

  2012cites this paper
• Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective.

  2012cites this paper
• Tissue Biomarkers for Prostate Cancer Radiation Therapy

  2012cites this paper
• High‐dose rate brachytherapy compared with open radical prostatectomy for the treatment of high‐risk prostate cancer: 10 year biochemical freedom from relapse

  2012cites this paper
• Combined hormone therapy and radiation therapy for locally advanced prostate cancer.

  2012cites this paper
• Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

  2012cites this paper
• Role of hormonal therapy for prostate cancer: perspective from Japanese experiences

  2012cites this paper
• Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer

  2012cites this paper
• Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06.

  2011influential citation
• Evaluación y opciones de tratamiento en pacientes con falla posterior a la prostatectomía por cáncer localizado de la próstata

  2011cites this paper
• UZNAPREDOVALOG KARCINOMA PROSTATE TREATMENT OF LOCALLY ADVANCED PROSTATIC CANCER

  2011cites this paper
• Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.

  2011cites this paper
• Contemporary Role of Endocrine Treatment in Patients with Localized or Locally Advanced Prostate Cancer: A Review

  2011cites this paper
• Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.

  2011cites this paper
• Prostatectomía radical retropúbica. Experiencia de 15 años en una institución privada

  2011cites this paper
• Molecular Targets for Radiation Oncology in Prostate Cancer

  2011cites this paper
• RANGE ADAPTIVE PROTON THERAPY FOR PROSTATE CANCER

  2010cites this paper
• The Use of Androgen Deprivation in Conjunction with Radiation in Localized Prostate Cancer~!2009-08-29~!2009-12-19~!2010-04-23~!

  2010cites this paper
• Reply to Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy by C. Heyns

  2010cites this paper
• TRETMAN LOKALNO UZNAPREDOVALOG KARCINOMA PROSTATE

  2010cites this paper
• [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].

  2010cites this paper
• External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

  2010cites this paper
• A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.

  2010cites this paper
• Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?

  2010cites this paper
• Guía clínica sobre el cáncer de próstata

  2010cites this paper
• Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

  2010cites this paper
• Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.

  2010cites this paper
• [Treatment of locally advanced prostatic cancer].

  2010cites this paper
• Radiothérapie et hormonothérapie pour le cancer de la prostate: acquis et interrogations

  2010cites this paper
• [High-risk clinically localised prostate cancer].

  2010cites this paper
• Hormone therapy in the management of prostate cancer: evidence-based approaches

  2010cites this paper
• Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapy.

  2009cites this paper
• What is New in Hormone Therapy for Prostate Cancer in 2007

  2008cites this paper
• Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo

  2008cites this paper
• Radiotherapie beim lokal fortgeschrittenen Prostatakarzinom

  2008cites this paper
• Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen-Deprivation Therapy

  2008cites this paper
• Modern External-Beam Radiation Therapy for Prostate Cancer: How and When?

  2008cites this paper
• Hormonothérapie adjuvante à la radiothérapie

  2008cites this paper
• Hormone therapy and radiotherapy for intermediate risk prostate cancer.

  2008cites this paper
• Multidisciplinary Management of the Prostate Cancer Patient: Introduction and Conclusions

  2008cites this paper
• [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].

  2008cites this paper
• Clinical stage T3 prostate cancer: the added value of three-dimensional conformal/intensity-modulated external-beam radiotherapy.

  2008cites this paper
• Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study

  2007cites this paper
• Adenovirus-mediated p53 gene transfer sensitizes hepatocellular carcinoma cells to heavy-ion radiation

  2007cites this paper
• Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer

  2007cites this paper
• No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro

  2007cites this paper
• Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: a prospective study of 402 patients.

  2007cites this paper
• Radiation therapy in prostate cancer.

  2007cites this paper
• What dose of external-beam radiation is high enough for prostate cancer?

  2007cites this paper
• Early effects of pharmacological androgen deprivation in human prostate cancer

  2007cites this paper
• Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta‐analysis of randomized controlled trials

  2007cites this paper
• The role of hormonal treatment in prostate cancer.

  2007cites this paper
• Radiotherapy for the Treatment of Locally Advanced Prostate Cancer

  2007cites this paper
• Profil de tolérance du bicalutamide 150 mg (revue de la littérature et avis d'experts)

  2007cites this paper
• Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?

  2006cites this paper
• Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.

  2006cites this paper
• Radiation therapy combined with hormone therapy for prostate cancer.

  2006cites this paper
• [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].

  2006cites this paper
• [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].

  2005cites this paper
• Evaluating the Addition of Total Androgen Suppression to Radiation versus Radiation Alone for Locally Advanced Prostate Cancer

  2005cites this paper
• Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.

  2005cites this paper
• Heat shock protein 90 (Hsp90) chaperone complex inhibitor, Radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor

  2005cites this paper
• Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.

  2005cites this paper
• Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation via Manipulation of the MDM2 Pathway

  2005cites this paper
• Cancer de la prostate à haut risque de rechute. Résultats d'une RT-HT de 12 mois

  2005cites this paper
• Place de l'association de radiothérapie et d'hormonothérapie dans les cancers de la prostate

  2005cites this paper
• Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.

  2005cites this paper
• [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].

  2005cites this paper
• Early versus late hormonal therapy for prostate cancer

  2004cites this paper
• Human Checkpoint Protein hRad9 Functions as a Negative Coregulator To Repress Androgen Receptor Transactivation in Prostate Cancer Cells

  2004cites this paper
• Apoptotic impact of α1‐blockers on prostate cancer growth: A myth or an inviting reality?

  2004cites this paper
• Brachyterápiás boost besugárzás nagy kockázatú, lokalizált prosztatarák kezelésében: elsô hazai tapasztalatok.

  2004cites this paper
• Androgen Deprivation and Radiation Therapy for Localized Prostate Cancer

  2004cites this paper
• Pattern of Proliferative Index (Ki-67) After Anti-Androgen Manipulation Reflects the Ability of Irradiation to Control Prostate Cancer

  2004cites this paper
• Early versus late hormonal therapy for prostate cancer

  2004cites this paper
• Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.

  2003cites this paper
• Treatment of prostate cancer with regional lymph node (N1) metastasis.

  2003cites this paper
• RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

  2003cites this paper
• Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.

  2003cites this paper